Key AUA 2026 abstracts to watch: immunotherapy for NMIBC and radioligand therapy for mHSPC
The American Urological Association 2026 meeting will feature several highly anticipated abstracts.
Experts say immunotherapy for non‑muscle‑invasive bladder cancer is a major focus, reflecting growing interest in checkpoint inhibitors and novel agents.
A second spotlight is on radioligand therapy for metastatic hormone‑sensitive prostate cancer, where early data suggest potential benefits.
These presentations are expected to shape future clinical trials and may influence drug development pipelines.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “IO in NMIBC, Radioligand Therapy in mHSPC Highlight Key Presentations to Watch at AUA 2026”
read at onclive ↗
comments(0)
5-min edit window · permanent after that